GlobeStar Therapeutics Corporation (GSTC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.94 Million USD | 9.29% |
| 2022 | -1.64 Million USD | 83.04% |
| 2021 | -9.66 Million USD | -1139.98% |
| 2020 | -779.79 Thousand USD | 24.69% |
| 2019 | -1.03 Million USD | -26.78% |
| 2018 | -816.74 Thousand USD | 51.38% |
| 2017 | -1.67 Million USD | 48.98% |
| 2016 | -3.29 Million USD | -203.29% |
| 2015 | -1.08 Million USD | 12.81% |
| 2014 | -1.24 Million USD | -31.61% |
| 2013 | -946.11 Thousand USD | 13.11% |
| 2012 | -1.08 Million USD | -1912.44% |
| 2011 | -54.1 Thousand USD | -2503.71% |
| 2010 | -2078.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -174.96 Thousand USD | -6.84% |
| 2024 Q3 | -197.66 Thousand USD | -12.97% |
| 2024 Q1 | -163.75 Thousand USD | 53.29% |
| 2023 Q3 | -1.28 Million USD | -669.86% |
| 2023 Q2 | -166.59 Thousand USD | 5.65% |
| 2023 Q1 | -176.57 Thousand USD | 42.73% |
| 2023 FY | -1.48 Million USD | 9.29% |
| 2023 Q4 | -350.57 Thousand USD | 72.67% |
| 2022 Q1 | -332.84 Thousand USD | 92.19% |
| 2022 Q2 | -688.55 Thousand USD | -106.87% |
| 2022 FY | -1.64 Million USD | 83.04% |
| 2022 Q4 | -308.3 Thousand USD | -95.0% |
| 2022 Q3 | -158.1 Thousand USD | 77.04% |
| 2021 Q4 | -4.26 Million USD | 5.66% |
| 2021 Q2 | -895.83 Thousand USD | -620.15% |
| 2021 Q3 | -4.51 Million USD | -404.39% |
| 2021 FY | -9.66 Million USD | -1139.98% |
| 2021 Q1 | -124.39 Thousand USD | 28.67% |
| 2020 FY | -779.79 Thousand USD | 24.69% |
| 2020 Q1 | -161.03 Thousand USD | -3.21% |
| 2020 Q2 | -118.31 Thousand USD | 26.53% |
| 2020 Q4 | -174.39 Thousand USD | -98.21% |
| 2020 Q3 | -87.98 Thousand USD | 25.63% |
| 2019 Q2 | -190.26 Thousand USD | 42.04% |
| 2019 Q3 | -540.00 USD | 99.72% |
| 2019 Q4 | -156.02 Thousand USD | -28793.7% |
| 2019 Q1 | -328.24 Thousand USD | -49.07% |
| 2019 FY | -1.03 Million USD | -26.78% |
| 2018 Q3 | -90.98 Thousand USD | -126.26% |
| 2018 Q1 | -465.35 Thousand USD | 52.72% |
| 2018 FY | -816.74 Thousand USD | 51.38% |
| 2018 Q4 | -220.19 Thousand USD | -142.01% |
| 2018 Q2 | -40.21 Thousand USD | 91.36% |
| 2017 FY | -1.67 Million USD | 48.98% |
| 2017 Q4 | -984.32 Thousand USD | -438.91% |
| 2017 Q3 | -182.65 Thousand USD | 6.53% |
| 2017 Q2 | -195.4 Thousand USD | 38.44% |
| 2017 Q1 | -317.41 Thousand USD | 0.0% |
| 2016 Q3 | -84.96 Thousand USD | 59.48% |
| 2016 FY | -3.29 Million USD | -203.29% |
| 2016 Q2 | -209.67 Thousand USD | -1.04% |
| 2016 Q1 | -207.52 Thousand USD | 28.24% |
| 2015 Q2 | -304.27 Thousand USD | -34.85% |
| 2015 FY | -1.08 Million USD | 12.81% |
| 2015 Q1 | -225.64 Thousand USD | -4.72% |
| 2015 Q4 | -289.18 Thousand USD | -8.49% |
| 2015 Q3 | -266.55 Thousand USD | 12.4% |
| 2014 Q4 | -215.46 Thousand USD | 57.13% |
| 2014 Q2 | -181.56 Thousand USD | 52.29% |
| 2014 FY | -1.24 Million USD | -31.61% |
| 2014 Q3 | -502.62 Thousand USD | -176.83% |
| 2014 Q1 | -380.52 Thousand USD | 12.84% |
| 2013 Q1 | -96 Thousand USD | 50.76% |
| 2013 Q4 | -436.59 Thousand USD | -145.8% |
| 2013 FY | -946.11 Thousand USD | 13.11% |
| 2013 Q3 | -177.62 Thousand USD | 24.7% |
| 2013 Q2 | -235.89 Thousand USD | -145.7% |
| 2012 Q4 | -194.98 Thousand USD | 73.0% |
| 2012 Q3 | -722.21 Thousand USD | -602.1% |
| 2012 Q2 | -102.86 Thousand USD | -49.59% |
| 2012 Q1 | -68.76 Thousand USD | -112.07% |
| 2012 FY | -1.08 Million USD | -1912.44% |
| 2011 Q2 | -2101.00 USD | 2.28% |
| 2011 Q1 | -2150.00 USD | 0.0% |
| 2011 Q3 | -17.42 Thousand USD | -729.56% |
| 2011 Q4 | -32.42 Thousand USD | -86.04% |
| 2011 FY | -54.1 Thousand USD | -2503.71% |
| 2010 FY | -2078.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -45.964% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 72.085% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 103.679% |
| Nascent Biotech, Inc. | -2.08 Million USD | 6.631% |
| Rebus Holdings, Inc. | -1.02 Million USD | -91.103% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.993% |
| Qrons Inc. | -789.34 Thousand USD | -146.944% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -208.227% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 96.886% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -369.157% |
| Skye Bioscience, Inc. | -37.64 Million USD | 94.822% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.4% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 70.359% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -612.961% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.547% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 32.608% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -7.071% |
| Mesoblast Limited | -87.95 Million USD | 97.784% |
| Marizyme, Inc. | -65.34 Million USD | 97.017% |
| Genus plc | 7.9 Million USD | 124.674% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 82.103% |
| Pharming Group N.V. | -10.54 Million USD | 81.52% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 10.165% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 47.463% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 77.96% |
| ContraFect Corporation | -65.15 Million USD | 97.008% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 60.106% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -12.839% |
| IMV Inc. | -36.48 Million USD | 94.657% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 75.815% |
| MultiCell Technologies, Inc. | -380.07 USD | -512765.788% |
| ONE Bio Corp. | 8.67 Million USD | 122.466% |
| Accustem Sciences Inc. | -3.74 Million USD | 47.97% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 96.229% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -53.831% |
| Q BioMed Inc. | -2.05 Million USD | 5.012% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 47.783% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 18.129% |
| Biomind Labs Inc. | -1.21 Million USD | -60.522% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 96.736% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 37.157% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 75.336% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -12915.819% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 87.719% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 66.492% |
| GB Sciences, Inc. | -1.36 Million USD | -43.151% |
| Alpha Cognition Inc. | -13.77 Million USD | 85.847% |
| HST Global, Inc. | -146.21 Thousand USD | -1233.184% |
| CSL Limited | 2.64 Billion USD | 100.074% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -11.083% |
| Halberd Corporation | -79.67 Thousand USD | -2346.469% |
| Enzolytics Inc. | -2.17 Million USD | 10.455% |
| Agentix Corp. | -1.37 Million USD | -41.845% |
| Resverlogix Corp. | -3.61 Million USD | 46.004% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 38.537% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.339% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2089.03% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 128.15% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 50.938% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 35.586% |
| AVAX Technologies, Inc. | -6.41 Million USD | 69.608% |
| Zenith Capital Corp. | -10.59 Million USD | 81.604% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.958% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -8286.752% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 52.984% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -3125.065% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 2.786% |
| Kadimastem Ltd | -3.3 Million USD | 41.064% |
| Helix BioMedix, Inc. | -1.05 Million USD | -84.578% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 48.959% |
| BioStem Technologies, Inc. | -8.48 Million USD | 77.022% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -341.637% |
| LadRx Corporation | 400.44 Thousand USD | 586.773% |
| Cell Source, Inc. | -5.32 Million USD | 63.368% |
| Regen BioPharma, Inc. | 1.02 Million USD | 290.448% |
| Regen BioPharma, Inc. | 1.02 Million USD | 290.448% |
| NovAccess Global Inc. | -4.76 Million USD | 59.128% |
| Affymax, Inc. | -14.42 Million USD | 86.486% |
| Itoco Inc. | -1.86 Million USD | -4.294% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 56.123% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -16.791% |
| Mobile Lads Corp. | -2.26 Million USD | 13.875% |
| CytoDyn Inc. | -49.84 Million USD | 96.089% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2366.374% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -754.458% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -107.03% |
| SYBLEU INC | -180.3 Thousand USD | -981.09% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -20.866% |
| International Stem Cell Corporation | -131 Thousand USD | -1387.976% |
| Bioxytran, Inc. | -4.28 Million USD | 54.457% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -3491.629% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 22.962% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 95.945% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 7.793% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -149.62% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 38.471% |
| Neutra Corp. | -233.46 Thousand USD | -734.921% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 90.394% |
| PureTech Health plc | -65.69 Million USD | 97.033% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 90.834% |
| IXICO plc | -1.17 Million USD | -65.471% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 80.364% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 96.588% |
| CSL Limited | 2.64 Billion USD | 100.074% |
| Cellectis S.A. | -103.17 Million USD | 98.111% |